FORT WORTH, Texas, June 3 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc. (formerly MB Software Corporation (OTC Bulletin Board: MBSB)) announced today that it will begin an evidence based study evaluating the clinical performance of their advanced wound care collagen product, CellerateRx(R) on skin tears. Skin tears represent a major problem in the elderly and compromised patients. It is estimated that at least 1.5 million skin tears occur in institutionalized patients(1) with prevalence rates between 14-24%. "Skin tears can be a significant problem in the elderly due to loss of dermal tissue thickness, as well as other contributing factors such as comprised nutritional status and decreased mobility," said VP of Corporate Development Cathy Bradshaw. "Untreated skin tears can also serve as a portal of entry for local and systemic infection as well as a source of pain for the patient. Their treatment can have an impact on the facilities' financial resources and nursing time. We have had an excellent response from clinicians with Cellerate on skin tears and are looking forward to providing the medical community with evidence based data."
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (formerly MB Software Corp OTCBB: MBSB), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company's Website at www.CellerateRX.com .
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events. Compensation Disclaimer: Capital Pros Network CPN has been compensated the equivalent of $50,000 from MBSB.OB. Certain oral statements made by management from time to time and certain statements contained in press releases and periodic reports issued by Capital Pros Network or MBSB.OB (the "Company"), as well as those contained herein, that are not historical facts are "forward-looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934 and, because such statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
(1) ECPN January 2007
SOURCE Wound Management Technologies, Inc.
